Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease

Mitral valve disease (MVD) is a frequent cause of heart failure and death worldwide, but its etiopathogenesis is not fully understood. Interleukin (IL)-33 regulates inflammation and thrombosis in the vascular endothelium and may play a role in the atherosclerotic process, but its role in mitral valv...

Full description

Bibliographic Details
Main Authors: Amaia Garcia-Pena, Jaime Ibarrola, Adela Navarro, Alba Sadaba, Carolina Tiraplegui, Mattie Garaikoetxea, Vanessa Arrieta, Lara Matilla, Amaya Fernández-Celis, Rafael Sadaba, Virginia Alvarez, Alicia Gainza, Eva Jover, Natalia López-Andrés
Format: Article
Language:English
Published: MDPI AG 2021-02-01
Series:International Journal of Molecular Sciences
Subjects:
ST2
Online Access:https://www.mdpi.com/1422-0067/22/5/2310
id doaj-8f17dc587d114a42accba79e04fd8830
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Amaia Garcia-Pena
Jaime Ibarrola
Adela Navarro
Alba Sadaba
Carolina Tiraplegui
Mattie Garaikoetxea
Vanessa Arrieta
Lara Matilla
Amaya Fernández-Celis
Rafael Sadaba
Virginia Alvarez
Alicia Gainza
Eva Jover
Natalia López-Andrés
spellingShingle Amaia Garcia-Pena
Jaime Ibarrola
Adela Navarro
Alba Sadaba
Carolina Tiraplegui
Mattie Garaikoetxea
Vanessa Arrieta
Lara Matilla
Amaya Fernández-Celis
Rafael Sadaba
Virginia Alvarez
Alicia Gainza
Eva Jover
Natalia López-Andrés
Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
International Journal of Molecular Sciences
interleukin-33
ST2
mitral valve
myxomatous
valve endothelial cells
valve interstitial cells
author_facet Amaia Garcia-Pena
Jaime Ibarrola
Adela Navarro
Alba Sadaba
Carolina Tiraplegui
Mattie Garaikoetxea
Vanessa Arrieta
Lara Matilla
Amaya Fernández-Celis
Rafael Sadaba
Virginia Alvarez
Alicia Gainza
Eva Jover
Natalia López-Andrés
author_sort Amaia Garcia-Pena
title Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
title_short Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
title_full Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
title_fullStr Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
title_full_unstemmed Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve Disease
title_sort activation of the interleukin-33/st2 pathway exerts deleterious effects in myxomatous mitral valve disease
publisher MDPI AG
series International Journal of Molecular Sciences
issn 1661-6596
1422-0067
publishDate 2021-02-01
description Mitral valve disease (MVD) is a frequent cause of heart failure and death worldwide, but its etiopathogenesis is not fully understood. Interleukin (IL)-33 regulates inflammation and thrombosis in the vascular endothelium and may play a role in the atherosclerotic process, but its role in mitral valve has not been investigated. We aim to explore IL-33 as a possible inductor of myxomatous degeneration in human mitral valves. We enrolled 103 patients suffering from severe mitral regurgitation due to myxomatous degeneration undergoing mitral valve replacement. Immunohistochemistry of the resected leaflets showed IL-33 and ST2 expression in both valve interstitial cells (VICs) and valve endothelial cells (VECs). Positive correlations were found between the levels of IL-33 and molecules implicated in the development of myxomatous MVD, such as proteoglycans, extracellular matrix remodeling enzymes (matrix metalloproteinases and their tissue inhibitors), inflammatory and fibrotic markers. Stimulation of single cell cultures of VICs and VECs with recombinant human IL-33 induced the expression of activated VIC markers, endothelial–mesenchymal transition of VECs, proteoglycan synthesis, inflammatory molecules and extracellular matrix turnover. Our findings suggest that the IL-33/ST2 system may be involved in the development of myxomatous MVD by enhancing extracellular matrix remodeling.
topic interleukin-33
ST2
mitral valve
myxomatous
valve endothelial cells
valve interstitial cells
url https://www.mdpi.com/1422-0067/22/5/2310
work_keys_str_mv AT amaiagarciapena activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT jaimeibarrola activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT adelanavarro activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT albasadaba activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT carolinatiraplegui activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT mattiegaraikoetxea activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT vanessaarrieta activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT laramatilla activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT amayafernandezcelis activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT rafaelsadaba activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT virginiaalvarez activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT aliciagainza activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT evajover activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
AT natalialopezandres activationoftheinterleukin33st2pathwayexertsdeleteriouseffectsinmyxomatousmitralvalvedisease
_version_ 1724250251571757056
spelling doaj-8f17dc587d114a42accba79e04fd88302021-02-26T00:07:04ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672021-02-01222310231010.3390/ijms22052310Activation of the Interleukin-33/ST2 Pathway Exerts Deleterious Effects in Myxomatous Mitral Valve DiseaseAmaia Garcia-Pena0Jaime Ibarrola1Adela Navarro2Alba Sadaba3Carolina Tiraplegui4Mattie Garaikoetxea5Vanessa Arrieta6Lara Matilla7Amaya Fernández-Celis8Rafael Sadaba9Virginia Alvarez10Alicia Gainza11Eva Jover12Natalia López-Andrés13Cardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainCardiovascular Translational Research, Navarrabiomed (Miguel Servet Foundation), Complejo Hospitalario de Navarra (CHN), Universidad Pública de Navarra (UPNA), IdiSNA. Irunlarrea 3, 31008 Pamplona, SpainMitral valve disease (MVD) is a frequent cause of heart failure and death worldwide, but its etiopathogenesis is not fully understood. Interleukin (IL)-33 regulates inflammation and thrombosis in the vascular endothelium and may play a role in the atherosclerotic process, but its role in mitral valve has not been investigated. We aim to explore IL-33 as a possible inductor of myxomatous degeneration in human mitral valves. We enrolled 103 patients suffering from severe mitral regurgitation due to myxomatous degeneration undergoing mitral valve replacement. Immunohistochemistry of the resected leaflets showed IL-33 and ST2 expression in both valve interstitial cells (VICs) and valve endothelial cells (VECs). Positive correlations were found between the levels of IL-33 and molecules implicated in the development of myxomatous MVD, such as proteoglycans, extracellular matrix remodeling enzymes (matrix metalloproteinases and their tissue inhibitors), inflammatory and fibrotic markers. Stimulation of single cell cultures of VICs and VECs with recombinant human IL-33 induced the expression of activated VIC markers, endothelial–mesenchymal transition of VECs, proteoglycan synthesis, inflammatory molecules and extracellular matrix turnover. Our findings suggest that the IL-33/ST2 system may be involved in the development of myxomatous MVD by enhancing extracellular matrix remodeling.https://www.mdpi.com/1422-0067/22/5/2310interleukin-33ST2mitral valvemyxomatousvalve endothelial cellsvalve interstitial cells